On October 28, HHS said it would stop taking action against licensed pharmacies that compound six popular peptides, including BPC-157 and TB-500, the pair sold online as the "Wolverine stack." For a market that's run on gray-market vials for years, that sounds like a turning point. To sort out what changed and what didn't, we sat down with Dr. Christopher Robinson, a Johns Hopkins physician-scientist who specializes in pain and regenerative medicine. Robinson calls himself pro-peptide and has applied for funding to test one. That's what makes his read on the evidence worth hearing.